Table 2 Main toxicities according to the National Cancer Institute Common Toxicity Criteria version 3 (treatment-related toxicities)

From: A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer

 

All grades

Grade 3/4

 

Cis/Doc ( n =43)

Ox/Doc ( n =44)

 

Cis/Doc ( n =43)

Ox/Doc ( n =44)

 
 

No.

%

No.

%

P -value

No.

%

No.

%

P -value

Haematologic

Anaemia

33

76.7

30

68.2

NS

1

2.3

5

11.4

NS

Leukopenia

36

83.7

27

61.4

0.0300

19

44.2

6

13.6

0.0020

Neutropenia

31

72.1

26

59.1

NS

24

55.8

12

27.3

0.0091

Thrombocytopenia

14

32.6

7

15.9

NS

4

9.3

0

0

0.0554

Gastrointestinal

Nausea

39

90.7

38

86.3

NS

10

23.6

10

22.7

NS

Vomitting

25

58.1

22

50

NS

6

14

2

4.5

NS

Diarrhoea

28

65.1

25

56.8

NS

8

18.6

4

9.1

NS

Constipation

12

27.9

8

18.2

NS

0

0

0

0

NS

Stomatitis

24

55.8

17

38.6

NS

4

9.3

1

2.3

NS

Hepatic

AST/ALT

7

16.3

15

34.1

NS

1

2.3

2

4.5

NS

ALP

7

16.3

9

20.5

NS

0

0

1

2.3

NS

Neurologic

Neurosensory

23

53.5

27

61.4

NS

1

2.3

2

4.5

NS

Others

Alopecia

38

88.4

31

70.5

NS

33

76.4

12

27.3

>0.0001

Fatigue

35

81.4

26

59.1

0.0344

9

20.1

9

20.5

NS

Creatinine

24

55.8

5

11.4

>0.0001

1

2.3

1

2.3

NS

Weight loss

18

41.9

12

27.3

NS

1

2.3

0

0

NS

Infection

18

41.9

13

29.5

NS

11

25.6

4

9.1

0.0507

Fever

10

23.6

8

18.2

NS

0

0

0

0

NS

  1. Abbreviations: Cis/Doc=cisplatin/docetaxel; Ox/Doc=oxaliplatin/docetaxel; AST/ALT=aspartate aminotransferase/alanine aminotransferase; ALP=alkaline phosphatase; NS=not significant. Bold numbers indicate statistically significant differences.
Back to article page